Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

被引：0
|
作者：
Flinn, Ian [1 ]
Brunvand, Mark [2 ]
Dyer, Martin J. S. [3 ]
Hillman, Peter [4 ]
Jones, Jeffrey [5 ]
Lymp, James [6 ]
Elhamy, Mostafa [6 ]
Vosganian, Gregory [6 ]
Huang, Jane [6 ]
Kipps, Thomas J. [7 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Colorado Blood Canc Inst, Denver, CO USA
[3] Univ Leicester, Leicester, Leics, England
[4] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
[5] Ohio State Univ, Sch Med, Columbus, OH 43210 USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] REDUCTION OF TUMOR LYSIS SYNDROME (TLS) RISK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH ABT-199 (GDC-0199): RESULTS OF MODIFICATIONS TO DOSING SCHEDULE AND TLS PROPHYLAXIS
    Seymour, J.
    Roberts, A.
    Stilgenbauer, S.
    Gressick, L. A.
    Rudersdorf, N. K.
    Busman, T.
    Munasinghe, W.
    Wong, S.
    Desai, M.
    Best, A. E.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    HAEMATOLOGICA, 2014, 99 : 321 - 321
  • [32] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    Davids, Matthew Steven
    Seymour, John Francis
    Gerecitano, John F.
    Kahl, Brad S.
    Pagel, John M.
    Wierda, William G.
    Anderson, Mary Ann
    Darden, David E.
    Nolan, Cathy E.
    Gressick, Lori A.
    Yang, Jianning
    Chyla, Brenda J.
    Busman, Todd A.
    Graham, Alison M.
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] An immunoassay detecting Bcl-2: Bim and Mcl-1: Bim complexes in the phase 1 monotherapy study of the Bcl-2 inhibitor, ABT-199/GDC-0199, in chronic lymphocytic leukemia patients
    Li, Jessica
    Chen, Jun
    Kadel, Ward
    Chyla, Brenda
    McKeegan, Evelyn
    Punnoose, Elizabeth
    Darbonne, Walter
    CANCER RESEARCH, 2014, 74 (19)
  • [34] A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Swinnen, Lode
    Kozloff, Mark
    Wang, Ding
    Reid, Erin
    Nastoupil, Loretta
    Fowler, Nathan
    Cordero, Jaclyn
    D'Amico, Diane
    Diehl, Susan
    Dunbar, Martin
    Zhu, Ming
    Wong, Shekman
    Enschede, Sari Heitner
    Chien, David
    Humerickhouse, Rod A.
    Flowers, Christopher
    BLOOD, 2015, 126 (23)
  • [35] A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy
    DiNardo, Courtney
    Pollyea, Daniel
    Pratz, Keith
    Thirman, Michael J.
    Letai, Anthony
    Frattini, Mark
    Jonas, Brian
    Leverson, Joel
    Zhu, Ming
    Dunbar, Martin
    Falotico, Nancy
    Kirby, Rachel
    Agarwal, Suresh
    Mabry, Mack
    Potluri, Jalaja
    Humerickhouse, Rod A.
    Kantarjian, Hagop M.
    Konopleva, Marina
    BLOOD, 2015, 126 (23)
  • [36] Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study
    Stilgenbauer, Stephan
    Eichhorst, Barbara F.
    Schetelig, Johannes
    Coutre, Steven
    Seymour, John F.
    Munir, Talha
    Puvvada, Soham D.
    Wendtner, Clemens-Martin
    Roberts, Andrew W.
    Jurczak, Wojciech
    Mulligan, Stephen
    Boettcher, Sebastian
    Mobasher, Mehrdad
    Zhu, Ming
    Chyla, Brenda
    Verdugo, Maria
    Enschede, Sari Heitner
    Cerri, Elisa
    Humerickhouse, Rod A.
    Gordon, Gary
    Hallek, Michael
    Wierda, William
    BLOOD, 2015, 126 (23)
  • [37] GREEN study: preliminary safety results from a phase IIIb trial of obinutuzumab alone or in combination with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia
    Bosch, Francesc
    Knauf, Wolfgang
    Robinson, Sue
    Montillo, Marco
    Dilhuydy, Marie-Sarah
    Mendoza, Maria
    Bernhardt, Alf
    Lasserre, Susan
    Foa, Robin
    Stilgenbauer, Stephan
    Leblond, Veronique
    LEUKEMIA & LYMPHOMA, 2015, 56 : 141 - 143
  • [38] Multicenter, phase III, open-label, randomized study in relapsed/refractory CLI, to evaluate the benefit of GDC-0199 (ABT-199) plus rituximah compared with bendamustine plus rituximab.
    Mobasher, Mehrdad
    Huang, Jane
    Elstrom, Rebecca L.
    Elhamy, Mostafa
    Bernaards, Coen
    Hallek, Michael J.
    Hillmen, Peter
    Kater, Arnon Philip
    Kipps, Thomas J.
    Seymour, John Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Phase I Study of ABT-199 (GDC-0199) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Responses Observed in Diffuse Large B-Cell (DLBCL) and Follicular Lymphoma (FL) at Higher Cohort Doses
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 18 - 19
  • [40] Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
    Leblond, Veronique
    Aktan, Melih
    Ferra Coll, Christelle M.
    Dartigeas, Caroline
    Kisro, Jens
    Montillo, Marco
    Raposo, Joao
    Merot, Jean-Louis
    Robson, Susan
    Gresko, Ekaterina
    Bosch, Francesc
    Stilgenbauer, Stephan
    Foa, Robin
    HAEMATOLOGICA, 2018, 103 (11) : 1889 - 1898
12345